|
Video: What is a Stock Split?
|
|
Coherus BioSciences is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Co. in-licensed its lead immuno-oncology product candidate, toripalimab (CHS-007), an anti-PD-1 antibody, from Shanghai Junshi Biosciences Co., Ltd. Toripalimab is being evaluated in late-stage clinical trials for the treatment of a range of tumor types. Co.'s commercial portfolio includes two U.S. Food and Drug Administration-approved biologics, including UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, a granulocyte-colony stimulating factor and YUSIMRY (adalimumab-aqvh), its Humira® (adalimumab) biosimilar product. According to our Coherus BioSciences stock split history records, Coherus BioSciences has had 2 splits. | |
|
Coherus BioSciences (CHRS) has 2 splits in our Coherus BioSciences stock split history database. The first split for CHRS took place on December 01, 1986. This was a 3 for 2
split, meaning for each 2
shares of CHRS owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. CHRS's second split took place on December 08, 1992. This was a 2 for 1
split, meaning for each share of CHRS owned pre-split, the shareholder now owned 2 shares. For example, a 1500 share position pre-split, became a 3000 share position following the split.
When a company such as Coherus BioSciences splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the Coherus BioSciences stock split history from start to finish, an original position size of 1000 shares would have turned into 3000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Coherus BioSciences shares, starting with a $10,000 purchase of CHRS, presented on a split-history-adjusted basis factoring in the complete Coherus BioSciences stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/21/2014 |
|
End date: |
05/03/2024 |
|
Start price/share: |
$13.05 |
|
End price/share: |
$2.27 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-82.61% |
|
Average Annual Total Return: |
-16.89% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,740.04 |
|
Years: |
9.45 |
|
|
|
Date |
Ratio |
12/01/1986 | 3 for 2
| 12/08/1992 | 2 for 1
|
|
|